Dataset Information

Acrylic Bone Cement Incorporated with Low Chitosan Loadings.

ABSTRACT: Despite the potential of acrylic bone cement (ABC) loaded with chitosan (CS) for orthopedic applications, there are only a few in vitro studies of this composite with CS loading ? 15 wt.% evaluated in bioactivity tests in simulated body fluid (SBF) for duration > 30 days. The purpose of the present work was to address this shortcoming of the literature. In addition to bioactivity, a wide range of cement properties were determined for composites with CS loading ranging from 0 to 20 wt.%. These properties included maximum exotherm temperature (Tmax), setting time (tset), water contact angle, residual monomer content, flexural strength, bending modulus, glass transition temperature, and water uptake. For cement with CS loading ? 15 wt.%, there was an increase in bioactivity, increase in biocompatibility, decrease in Tmax, increase in tset, all of which are desirable trends, but increase in residual monomer content and decrease in each of the mechanical properties, with each of these trends, were undesirable. Thus, a composite with CS loading of 15 wt.% should be further characterized to explore its suitability for use in low-weight-bearing applications, such as bone void filler and balloon kyphoplasty.

SUBMITTER: Valencia Zapata ME

PROVIDER: S-EPMC7408302 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Acrylic Bone Cement Incorporated with Low Chitosan Loadings.

Valencia Zapata Mayra Eliana ME Mina Hernandez José Herminsul JH Grande Tovar Carlos David CD

Polymers 20200721 7

Despite the potential of acrylic bone cement (ABC) loaded with chitosan (CS) for orthopedic applications, there are only a few in vitro studies of this composite with CS loading ≤ 15 wt.% evaluated in bioactivity tests in simulated body fluid (SBF) for duration > 30 days. The purpose of the present work was to address this shortcoming of the literature. In addition to bioactivity, a wide range of cement properties were determined for composites with CS loading ranging from 0 to 20 wt.%. These pr ...[more]

PMID: 32708078

Similar Datasets

Project description:Background and purposeThe purpose of this study was to investigate the effect of incorporating chitosan (Ch) and chitosan oligosaccharides (ChO) into the commercially premixed antibiotic-loaded bone cement (ALBC). We compare antibiotic release profiles, antibacterial activity, and mechanical properties among different ALBC formulations. The hypothesis was that increasing the amount of Ch and ChO in the cement mixture would increase the antibiotics released and bacterial control. ALBC mixed with Ch or ChO may create a greater effect due to its superior dissolving property.Materials and methodsThe bone cement samples used in this project were made from Copal® G+V composed of vancomycin and gentamicin. To prepare the Ch and the ChO mixed bone cement samples, different amounts of Ch and ChO were added to the polymethylmethacrylate matrix with three concentrations (1%, 5%, and 10%). Drug elution assay, antimicrobial assay, in vitro cytotoxicity, and mechanical properties were conducted.ResultsBone cement samples made from Copal® G+V alone or combined with Ch or ChO can release vancomycin and gentamicin into the phosphate-buffered saline. Mixing ChO into the bone cements can increase the amount of drug released more than Ch. ChO 10% gave the highest amount of antibiotics released. All samples showed good antibacterial properties with good biocompatibility in vitro. The microhardness values of the Ch and ChO groups increased significantly compared to the control group. In all groups tested, the microhardness of bone cements was reduced after the drug eluted out. However, this reduction of the Ch and ChO groups was in line with the control.InterpretationVarious attempts have been made to improve the ALBC efficacy. In our study, the best bone cement formulation was bone cement mixed with ChO (10%), which had the highest drug release profiles, was biocompatible, and contained antibacterial properties with acceptable mechanical properties. This phenomenon could result from the superior water solubility of the ChO. When ChO leaves the bone cement specimens, it generates pores that could act as a path that exposes the bone cement matrix to the surrounding medium, increasing antibiotic elution. From all above, ChO is a promising substance that could be added to ALBC in order to increase the drug elution rate. However, more in vitro and in vivo experiments are needed before being used in the clinic.

Project description:ObjectiveThis work focuses on tackling the inadequate bone/implant interface strength of acrylic bone cements, which is a formidable problem diminishing their clinical performance, especially in percutaneous kyphoplasty surgery.MethodsA new strategy of incorporating magnesium particles into clinically used poly(methylmethacrylate) (PMMA) bone cement to prepare a surface-degradable bone cement (SdBC) is proposed and validated both in vitro and in vivo.ResultsThis surface degradation characteristic enables osseointegrative, angiogenic and antiinfective properties. SdBC showed fast surface degradation and formed porous surfaces as designed, while the desirable high compressive strengths (≥70 MPa) of the cement were preserved. Besides, the SdBC with proper Mg content promoted osteoblast adhesion, spreading, proliferation and endothelial cell angiogenesis capacity compared with PMMA. Also, SdBC demonstrated clear inhibitory effect on Staphylococcus aureus and Escherichia coli. In vivo evaluation on SdBC by the rat femur defect model showed that the bone/implant interface strength was significantly enhanced in SdBC (push-out force of 11.8 ± 1.5 N for SdBC vs 7.0 ± 2.3N for PMMA), suggesting significantly improved osseointegration and bone growth induced by the surface degradation of the cement. The injectability, setting times and compressive strengths of SdBC with proper content of Mg particles (2.8 wt% and 5.4 wt%) were comparable with those of the clinical acrylic bone cement, while the heat release during polymerization was reduced (maximum temperature 78 ± 1 °C for PMMA vs 73.3 ± 1.5 °C for SdBC).ConclusionsThis work validates a new concept of designing bioactive bone/implant interface in PMMA bone cement. And this surface-degradable bone cement possesses great potential for minimally invasive orthopaedic surgeries such as percutaneous kyphoplasty.The translational potential of this articleThis work reports PMMA/Mg surface-degradable acrylic bone cements that possess enhanced osseointegrative, angiogenic and antiinfective properties that are lacking in the clinically used acrylic bone cements. This new kind of bone cements could improve the treatment outcome of many orthopaedic surgeries such as percutaneous kyphoplasty and arthroplasty.

Dataset Information

Acrylic Bone Cement Incorporated with Low Chitosan Loadings.

Publications

Acrylic Bone Cement Incorporated with Low Chitosan Loadings.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets